title: A novel treatment for vestibular disorder with FGLM-NH2 plus SSSR.
abstract: Topical FGLM-NH(2) (Phenylalanine-Glycine-Leucine-Methionine-Amide) plus SSSR (Serine-Serine-Serine-Arginine) facilitates recovery from vestibular disorders induced by (±)-α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) in guinea pigs and might offer a treatment strategy for patients with peripheral vestibular disorders. The tetrapeptide FGLM-NH(2) derived from substance P (SP) can be used to treat corneal disorders when combined with SSSR, which is a tetrapeptide derived from insulin-like growth factor-1 (IGF-1). We examined the influence of FGLM-NH(2) plus SSSR when locally applied to the unilateral inner ear of guinea pigs with vestibular disorder induced by AMPA. A total of 18 Hartley white guinea pigs were assigned to groups receiving either FGLM-NH(2) plus SSSR, artificial perilymph, or no treatment at all. A hole was drilled adjacent to the round window, with AMPA then infused into the hole in order to induce the vestibular disorder. Thereafter, FGLM-NH(2) plus SSSR or artificial perilymph was delivered via an osmotic pump that was inserted into the hole. Sinusoidal rotation tests were used for observing spontaneous nystagmus and for measurements of the vestibulo-ocular reflexes (VOR). Two animals from each group were immunohistochemically examined at 24h after the treatment. Spontaneous nystagmus decreased immediately after FGLM-NH(2) plus SSSR infusion. The recovery of the VOR gains was statistically faster than that seen in the control group at 3 and 7 days after treatment. Immunohistochemical examination revealed that many synaptic ribbons, which are markers of the synapse, were stained in the FGLM-NH(2) plus SSSR group compared with the untreated group. Topical application of FGLM-NH(2) plus SSSR accelerates functional recovery from AMPA-induced vestibular disorders by facilitating synaptic regeneration in guinea pigs.
authors.affiliation: Department of Otolaryngology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Toyota
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shimogori
authors.forename: Kazuma
authors.initials: K
authors.lastname: Sugahara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamashita
mesh_terms: D000818:Animals; D004359:Drug Therapy, Combination; D007758:Ear, Inner; D006168:Guinea Pigs; D007260:Infusion Pumps; D008297:Male; D009759:Nystagmus, Pathologic / Q000188:drug therapy / Q000503:physiopathology; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use*; D012027:Reflex, Vestibulo-Ocular / Q000187:drug effects; D012399:Rotation; D012665:Semicircular Canals / Q000378:metabolism; D013569:Synapses / Q000378:metabolism / Q000648:ultrastructure; D015837:Vestibular Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
chemical_list: D009842:Oligopeptides; C112946:phenylalanyl-glycyl-leucyl-methioninamide; C530429:seryl-seryl-seryl-arginine; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid